Eupraxia Pharmaceuticals (EPRX) News Today $6.19 +0.05 (+0.81%) Closing price 03:59 PM EasternExtended Trading$6.16 -0.04 (-0.57%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Weiss Ratings Reaffirms Sell (D-) Rating for Eupraxia Pharmaceuticals (NASDAQ:EPRX)October 9 at 2:17 AM | marketbeat.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 7 at 4:08 AM | marketbeat.comResearch Analysts Offer Predictions for EPRX Q3 EarningsOctober 7 at 2:13 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for EPRX Q3 Earnings?October 6 at 2:01 AM | marketbeat.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 2.5% - What's Next?October 4, 2025 | marketbeat.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for ...September 30, 2025 | finanznachrichten.deEupraxia announces ‘positive’ data from highest-dose cohort in RESOLVE trialSeptember 29, 2025 | msn.comEupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI ...September 29, 2025 | finance.yahoo.comEupraxia Pharmaceuticals Closes $80.5 Million Public OfferingSeptember 29, 2025 | tipranks.comEupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development ProgramsSeptember 29, 2025 | globenewswire.comIndependent Director of Eupraxia Pharmaceuticals Picks Up 13% More StockSeptember 29, 2025 | finance.yahoo.comEupraxia Pharmaceuticals Announces Major Share Offering to Boost CapitalSeptember 25, 2025 | theglobeandmail.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter OptionSeptember 24, 2025 | finanznachrichten.deEupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter OptionSeptember 24, 2025 | finance.yahoo.comEupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter OptionSeptember 24, 2025 | globenewswire.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common SharesSeptember 23, 2025 | finanznachrichten.deEupraxia Pharmaceuticals stock falls after pricing $70 million offeringSeptember 23, 2025 | za.investing.comEupraxia Pharmaceuticals Shares Drop After $70 Million Offering PricingSeptember 23, 2025 | msn.comEupraxia Pharmaceuticals announces common shares offering, no amount givenSeptember 22, 2025 | msn.comEupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common SharesSeptember 22, 2025 | globenewswire.comEupraxia Pharmaceuticals Announces Proposed Public Offering of Common SharesSeptember 22, 2025 | globenewswire.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Buy" by BrokeragesSeptember 14, 2025 | marketbeat.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 0% - Time to Sell?September 12, 2025 | marketbeat.comFirst Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GISeptember 2, 2025 | finance.yahoo.comWe're Keeping An Eye On Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn RateAugust 29, 2025 | uk.finance.yahoo.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Earns "Buy" Rating from HC WainwrightAugust 22, 2025 | marketbeat.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 20, 2025 | marketbeat.comEPRX FY2025 EPS Forecast Lowered by Cantor FitzgeraldAugust 19, 2025 | marketbeat.comQ3 EPS Estimate for Eupraxia Pharmaceuticals Cut by AnalystAugust 17, 2025 | marketbeat.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPSAugust 14, 2025 | marketbeat.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 13, 2025 | finanznachrichten.deEupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comScotia Capital Inc. Boosts Stock Holdings in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX)August 5, 2025 | marketbeat.comEupraxia Pharmaceuticals (EPRX) Expected to Announce Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comCantor Fitzgerald Forecasts EPRX FY2025 EarningsJuly 28, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX)July 25, 2025 | marketbeat.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of "Buy" from AnalystsJuly 24, 2025 | marketbeat.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 2.3% - Time to Sell?July 23, 2025 | marketbeat.comEupraxia Pharmaceuticals Invited to Present at Upcoming Investor ConferencesJuly 22, 2025 | financialpost.comFEupraxia Pharmaceuticals Invited to Present at Upcoming Investor ConferencesJuly 22, 2025 | financialpost.comFEupraxia Pharmaceuticals Invited to Present at Upcoming Investor ConferencesJuly 22, 2025 | globenewswire.comEupraxia Pharmaceuticals (EPRX) Receives a Buy from Raymond JamesJuly 11, 2025 | theglobeandmail.comEupraxia Pharma Shares Climb on Dosing of First EP-104GI Study PatientJuly 8, 2025 | marketwatch.comEupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic EsophagitisJuly 8, 2025 | globenewswire.comQ2 Earnings Estimate for EPRX Issued By HC WainwrightJune 30, 2025 | marketbeat.comEupraxia Pharmaceuticals Stock Short Interest Report | NASDAQ:EPRX - BenzingaJune 27, 2025 | benzinga.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded by HC Wainwright to "Strong-Buy" RatingJune 27, 2025 | marketbeat.comEupraxia Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:EPRX - BenzingaJune 26, 2025 | benzinga.comEupraxia Pharma director buys as stock tests top of rangeJune 26, 2025 | theglobeandmail.comHC Wainwright & Co. Initiates Coverage of Eupraxia Pharmaceuticals (EPRX) with Buy RecommendationJune 26, 2025 | msn.com Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EPRX Media Mentions By Week EPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPRX News Sentiment▼0.700.77▲Average Medical News Sentiment EPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPRX Articles This Week▼142▲EPRX Articles Average Week Get the Latest News and Ratings for EPRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Eupraxia Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Phathom Pharmaceuticals News Today Taysha Gene Therapies News Today Ginkgo Bioworks News Today CorMedix News Today Rezolute News Today Septerna News Today Xencor News Today Kodiak Sciences News Today Urogen Pharma News Today Maravai LifeSciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EPRX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
